Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Achillion Pharmaceuticals (ACHN)

Achillion Pharmaceuticals (ACHN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 946,718
  • Shares Outstanding, K 140,047
  • Annual Sales, $ 0 K
  • Annual Income, $ -70,270 K
  • 60-Month Beta 1.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.35
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.42
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/05/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.12
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.00 +12.67%
on 12/31/19
7.01 -3.64%
on 01/27/20
+0.69 (+11.37%)
since 12/27/19
3-Month
6.00 +12.67%
on 12/31/19
7.01 -3.64%
on 01/27/20
+0.52 (+8.33%)
since 10/25/19
52-Week
2.06 +228.16%
on 02/08/19
7.01 -3.64%
on 01/27/20
+4.48 (+196.49%)
since 01/25/19

Most Recent Stories

More News
Achillion Pharma Up 7.8% Since SmarTrend Uptrend Call (ACHN)

SmarTrend identified an Uptrend for Achillion Pharma (NASDAQ:ACHN) on October 16th, 2019 at $6.27. In approximately 4 months, Achillion Pharma has returned 7.81% as of today's recent price of $6.76.

ACHN : 6.76 (+10.28%)
Achillion Pharma Shares Up 7.8% Since SmarTrend's Buy Recommendation (ACHN)

SmarTrend identified an Uptrend for Achillion Pharma (NASDAQ:ACHN) on October 16th, 2019 at $6.27. In approximately 4 months, Achillion Pharma has returned 7.81% as of today's recent price of $6.76.

ACHN : 6.76 (+10.28%)
Achillion Pharma Shares Up 7.8% Since SmarTrend's Buy Recommendation (ACHN)

SmarTrend identified an Uptrend for Achillion Pharma (NASDAQ:ACHN) on October 16th, 2019 at $6.27. In approximately 4 months, Achillion Pharma has returned 7.81% as of today's recent price of $6.76.

ACHN : 6.76 (+10.28%)
Alexion Completes Acquisition of Achillion

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. The acquisition adds two clinical-stage oral small molecule Factor D inhibitors...

ACHN : 6.76 (+10.28%)
ALXN : 102.16 (-0.39%)
Global Glioblastoma Multiforme Drugs Market Projected Could Reach $1.4 Billion By 2025

Brain and other nervous system cancers are the 10th leading cause of death for men and women. The global Glioblastoma multiforme (GBM) drugs market to reach nearly $1.4 billion by 2025, expanding at a...

CNSP : 4.14 (+3.04%)
BCRX : 2.92 (+4.29%)
CLVS : 9.26 (-1.91%)
ACHN : 6.76 (+10.28%)
MGEN : 0.83 (+18.53%)
Achillion Pharma Set to Possibly Pullback After Yesterday's Rally of 12.89%

Achillion Pharma (NASDAQ:ACHN) traded in a range yesterday that spanned from a low of $6.88 to a high of $7.01. Yesterday, the shares gained 12.9%, which took the trading range above the 3-day high of...

ACHN : 6.76 (+10.28%)
Will Soliris, Ultomiris Drive Alexion's (ALXN) Q4 Earnings?

Alexion Inc.'s (ALXN) fourth-quarter 2019 results, scheduled to be reported on Jan 30, are likely to reflect solid performance of key drugs.

ACHN : 6.76 (+10.28%)
GILD : 67.01 (-0.81%)
ALXN : 102.16 (-0.39%)
BDSI : 5.32 (+0.95%)
Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study

Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.

ACHN : 6.76 (+10.28%)
AMGN : 221.69 (-0.80%)
ALXN : 102.16 (-0.39%)
APLS : 40.56 (-3.38%)
4 Reasons Why Investors Should Buy Alexion (ALXN) in 2020

Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction.

ACHN : 6.76 (+10.28%)
ALXN : 102.16 (-0.39%)
AMGN : 221.69 (-0.80%)
MITO : 2.25 (+0.45%)
Achillion Shareholders Approve Agreement to be Acquired by Alexion

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced...

ALXN : 102.16 (-0.39%)
ACHN : 6.76 (+10.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ACHN with:

Business Summary

ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused...

See More

Key Turning Points

2nd Resistance Point 7.11
1st Resistance Point 6.93
Last Price 6.76
1st Support Level 6.67
2nd Support Level 6.58

See More

52-Week High 7.01
Last Price 6.76
Fibonacci 61.8% 5.12
Fibonacci 50% 4.54
Fibonacci 38.2% 3.95
52-Week Low 2.06

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar